1979
DOI: 10.1007/bf00254740
|View full text |Cite
|
Sign up to set email alerts
|

Evaluation of early doxorubicin-induced cardiotoxicity by means of systolic time intervals

Abstract: Systolic time intervals (PEP/LVET ratio) were used for detection of acute variations in myocardial contractility after a single dose of 30, 60, or 75 mg of doxorubicin/m2. This drug induces an acute impairment of left ventricular function (increase in the PEP/LVET ratio) detectable 1 h after doxorubicin injection. The phenomenon appears to be dose-related, with a threshold dose of 30-40 mg/m2. The decrease in myocardial contractility is fully reversible within 24 h, at least after the first dose. This kind of … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
5
0

Year Published

1984
1984
2017
2017

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 18 publications
(5 citation statements)
references
References 3 publications
0
5
0
Order By: Relevance
“…Furthermore, a significant incidence of cardiovascular side effects namely hypotension, tachycardia, arrhythmias, and ultimately congestive heart failure were also described . Acute DOX side effects, including pericarditis‐myocarditis or arrhythmias, are generally reversible and clinically manageable . However, the mortality of patients that develop congestive heart failure after DOX chronic treatment can be as high as 50%, increasing significantly when cumulative doses higher than 500 mg/m 2 …”
Section: Introduction: Doxorubicin As a Cardiotoxic Anticancer Agentmentioning
confidence: 99%
“…Furthermore, a significant incidence of cardiovascular side effects namely hypotension, tachycardia, arrhythmias, and ultimately congestive heart failure were also described . Acute DOX side effects, including pericarditis‐myocarditis or arrhythmias, are generally reversible and clinically manageable . However, the mortality of patients that develop congestive heart failure after DOX chronic treatment can be as high as 50%, increasing significantly when cumulative doses higher than 500 mg/m 2 …”
Section: Introduction: Doxorubicin As a Cardiotoxic Anticancer Agentmentioning
confidence: 99%
“…Doxorubicin (DOX) is a leading therapeutic in clinical oncology, having a broad range of activity against both “liquid” and solid tumors, including lung cancers. ,, Since the discovery of DOX, thousands of other anthracyclines have been screened for their anticancer properties, but only few have emerged as clinically relevant . In spite of its immense acceptability, however, DOX causes a series of side effects, of particular relevance being its toxicity to the cardiac tissue. While DOX-induced cardiomyopathy is clinically manageable, it is associated with 50% mortality in those patients that develop congestive heart failure during treatment, , thus limiting the range of applicability of this powerful therapeutic. The ability to efficiently deliver DOX locally to the lungs and to improve DOX’s biodistribution by minimizing its concentration in the cardiac tissue may, therefore, represent an important step forward in the use of such a relevant anticancer therapeutic in the treatment of lung cancers.…”
Section: Introductionmentioning
confidence: 99%
“…In spite of its potent anticancer efficacy, the clinical use of DOX is hampered by cardiotoxicity, which manifests as either acute or chronic heart injury. Acute cardiotoxicity, including pericarditis, myocarditis, arrhythmias, and acute heart failure, occurs after receiving high doses of DOX and is clinically manageable (3,4). However, chronic DOX-induced cardiotoxicity is irreversible and more serious and may even develop to cardiomyopathy (5,6).…”
Section: Introductionmentioning
confidence: 99%